Please note: this event has passed
Structure: Presentation by speaker (~40 minutes) followed by a Q&A session (~20 minutes)
Speaker: Professor Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, St John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London
Professor Sophia Karagiannis is a translational cancer immunologist with academic and biotechnology experience in the USA and UK. She heads a cancer antibody discovery team focused on the crosstalk between patient immune cells and cancer, and on the design of novel agents for solid tumours such as melanoma, ovarian and breast cancer. Key areas of research include the study of patient-derived B cells and antibodies, and antibody-drug conjugates. Her group is the first internationally to design, evaluate and translate anti-tumour IgE class antibodies from concept to clinical testing. Sophia is founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE therapeutic agents for cancer. She is author of patents on antibody engineering for cancer therapy and serves as Secretary of the international AllergoOncology consortium, focused on the interface between Th2 immunity, allergies, IgE and cancer, which has become a recognised Working Group by the European Academy of Allergy and Clinical Immunology.